A prospective, observational study of bleeding and quality of life in subjects with Glanzmann thrombasthenia in the United Kingdom

Hemab Therapeutics0 个研究点目标入组 30 人开始时间: 2023年9月28日最近更新: 2024年4月29日

试验速览

2023 Results article in https://doi.org/10.1182/blood-2023-187558 (added 15/04/2024)

•Each participant must meet all of the following inclusion criteria to be eligible for enrollment in the study:
•1. Participant has signed the informed consent form
•2. =16 years of age
•3. Participant has confirmed GT (documented diagnosis on patient held registry document or clinical record)
•4. Participant has sufficient English language skills to complete the consent process, electronic questionnaires, and diary

•Each participant must not meet any of the following exclusion criteria to be eligible for enrolment in the study:
•1. Participant is currently pregnant
•2. Participant has a cancer diagnosis (excluding benign or localized disease eg. basal cell carcinoma of the skin) and is currently undergoing systemic treatment
•3. Participant has renal impairment currently requiring renal replacement therapy
•4. Participant has liver disease currently requiring treatment
•5. Participant has heart disease currently requiring treatment
•6. Participant is receiving current treatment with anticoagulation or anti-platelet therapies

发起方

Hemab Therapeutics